Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

FDA Approves RSV Monoclonal Antibody for Infants and Young Children

Emily Harris

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION（2023）

Cited 0|Views1
No score
Abstract
Nirsevimab-alip, marketed as Beyfortus by AstraZeneca, has received US Food and Drug Administration authorization for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children up to 2 years old.
More
Translated text
Key words
rsv monoclonal antibody,monoclonal antibody,infants,young children
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined